Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 21st World Congress on Radiology & Cancer Research Toronto, Ontario, Canada.

Day 2 :

Conference Series Radiology 2018 International Conference Keynote Speaker Myron R Szewczuk  photo
Biography:

For the past 37 years, Dr Szewczuk is Full Professor of Immunology and Medicine at Queen’s University, Kingston, ON Canada. Prior to Queen’s, he was Professor of Mucosal Immunology and Pathology at McMaster University, Hamilton, ON, Canada. He did his Postdoctoral training in cellular immunology at Cornell University Medical College, New York city, USA. Dr Szewczuk’s recent research has focused on the role of glycosylation in receptor activation with a particular focus of TOLL-like, nerve growth factor Trk, EGFR and insulin receptors. He has discovered a novel receptor-signaling platform and its targeted translation in multistage tumorigenesis

Abstract:

Stromal cells and growth factors play important roles during tumor initiation and progression. Growth factors not only mediate normal biological processes such as development and tissue repair but also tumorigenesis by contributing to proliferation and transformation in neoplastic cells. This study investigated the host angiogenic and pro-inflammatory cytokines during tumor initiation and progression in heterotopic xenografts of eGFP-MIAPaCa-2 tumors growing in RAGxCγ double mutant mice. The time-to-tumor progression revealed significant host cytokine responses initiated by the cancer cells in order for them to establish neo-vasculature for tumor growth. Here, cancer cells maneuver multiple hosts circulating angiogenic and pro-inflammatory cytokines by significantly reducing host angiostatic and pro-inflammatory cytokines that restrain tumor development and increasing those that are needed. Oseltamivir phosphate (OP) monotherapy when tumor volume reached 100-200mm3 revealed a reversal in some of the anti-angiogenic and pro-inflammatory cytokines in preventing tumor growth. The data signify several important cytokines as potential biomarkers for therapy. The findings identify for the first time how cancer cells surreptitiously use multiple host cytokines for tumor initiation and progression, all of which can be targeted by OP monotherapy

Keynote Forum

Rola Shaheen

Peterborough Regional Health Center, Canada

Keynote: The road map for high quality breast imaging practice
Conference Series Radiology 2018 International Conference Keynote Speaker Rola Shaheen photo
Biography:

Rola Shaheen, Medical Director and Chief of Radiology at Peterborough Regional Health Center in Ontario- Canada. She serves as provincial lead for Mammography Quality Management Program in partnership with Cancer Care Ontario and College of Physicians and Surgeons of Ontario and Regional Breast Imaging Lead for Mississauga- Halton Central West Region in OBSP. Previously she worked at SEHA in Abu Dhabi as lead breast imaging radiologist and chief of women’s imaging at Mafraq hospital. Graduated from Faculty of Medicine of Jordan University and completed radiology residency at University of Toronto. Completed women’s imaging fellowship at BIDMC-teaching hospital of Harvard Medical School.

Abstract:

Breast imaging practice is one of the most complex yet inetersting practices in any radiology department. Complexity stems from the fact that breast imaging is highly regulated specialty with key indicators meaurements in addition to the essential need for utilization of multi-modality equipments and image guided interventions to accurately establist the diagnosis of breast cancer and plan management accordingly. Providing high quality performance in breast imaging regradless of the setting is crucial to avoid any delay in diagnosis of breast cancer and equally important to is avoid unnecessary furher imaging or interventions to minimize patients’ anxiety and to enusre cost effectiveness. The knots and bolts for successful breast imaging practice include clear understanding of the highly regulated specialty in light of the collaborative multidisciplinary commitment. This talk will focus on providing an understanding of the multifaceted breast imaging practice of screening, diagnostic and interventions, and how the multimodality equipments (digital mammography, tomosynthesis, ultrasound & MRI) can serve realistically in each setting, in an effort to provide a high quality pateint centric, and cost effective practice. Pearls and pifalls will also be presented to help radiologists in every day breast practice.

Keynote Forum

Abdelmohsen Hussien

SUNY Upstate Medical University, USA

Keynote: Early Breast Cancer: Improve your ability to find it
Conference Series Radiology 2018 International Conference Keynote Speaker Abdelmohsen Hussien  photo
Biography:

Hussien is an American board certified radiologist. He has graduated from Cairo University Medical School. He also had his radiology residency in Egypt. He finished a four years of radiology fellowships in the University of Rochester in Neuroradiology, Body imaging and women’s imaging. He practiced women’s imaging for about 5 years, four of them at the University of Rochester. During which he was able to successfully make a great change in breast cancer detection rate in one of the affiliated locations in the town of Canandaigua. He then moved to SUNY Upstate Medical University for a wider scope of neuroradiology practice and research. 

Abstract:

Introduction: About 1 in 8 US women (about 12.4%) will develop invasive breast cancer over the course of her lifetime. In 2018, an estimated 266,120 new cases of invasive breast cancer are expected to be diagnosed in women in the US, along with 63,960 new cases of non-invasive (in situ) breast cancer. Detection of early invasive breast cancer is important, as patient survival is high when the cancer is 2 cm or smaller. Radiologists’ mission is to be able to detect breast cancer when it is very small, which is important in reducing breast cancer mortality. Women with invasive cancers of 1cm or smaller have a 95% chance of survival at 10 years, while those with invasive cancers 1–2 cm and 2–5 cm in size have, respectively, 85% and 60% survival at 10 years. There are many factors that govern the radiologists’ ability to detect breast cancer including their experience, number of hours per week reading screening mammogram, quality of imaging, availability of comparison, quality of the prior mammograms, distraction in the workplace, dedication to breast imaging, retrospective evaluation of the newly discovered cancers, awareness of the ACR updated regulations, and availability of the new technology such as tomosynthesis and high-resolution ultrasound. Properly managed breast imaging center is of similar importance to the aforementioned factors. Comprehensive breast cancer center staff should be aware that their ultimate goal is to help finding breast cancer and managing the diagnosed cancers, which requires a qualified leadership, a team spirit, dedication of each team member to what they do; from being careful how receptionists talk to the patient on the phone, how technologists get the best mammographic views, how a trained MR technologist can get the best MRI image possible to what is the exact job description of the nurse should be. Outline: In this review I will discuss: (a) Good quality mammogram (b) The different techniques to improve detailed screening mammogram evaluation and ways to improve the radiologist’s ability for early detection (c) The cancer behavior on imaging and how it can be deceptive to some less experienced mammographers (d) Hanging protocols (e) Evaluation of circular lesions, asymmetries, developing asymmetries, triangulation, areas of special attention (f) Mammographic abnormal patterns (g) Golden rules in evaluation of screening mammogram (h) Lymph nodes (i) Distractors (j) Radiologist- clinician interaction.
 

  • Cancer Therapy | Cancer Imaging | Nuclear Medicine | Radiology Imaging | Proton Theray Nuclear Medicine | Paediatric Oncology | Computer Assisted Tomography | Ultrasound Imaging | Musculoskeletal

Session Introduction

Mosa Alhamami

University of Toronto, Canada

Title: Manganese-enhanced magnetic resonance imaging of breast cancer cells
Speaker
Biography:

Mosa Alhamami earned his PhD from the University of Toronto for his work on manganese-enhanced MRI of breast cancers. His research was recognized with more than $130,000 of scholarships from local and federal funding sources and was nominated to represent the University of Toronto at the national competition for the Vanier Canada Graduate Scholarship and the provincial competition for the Ontario Women’s Health Scholars Award. Since July 2016, Dr Alhamami has been a Scientific Reviewer for the Journal of Magnetic Resonance Imaging and was recognized by the International Society for Magnetic Resonance in Medicine for his service to the journal.
 

Abstract:

There has been continued interest in engineering MRI contrast agents (CAs) and evaluating their diagnostic efficacy to overcome issues associated with clinically-approved CAs such as Gd-DTPA. Of particular interest are intracellular CAs that can provide sensitive identification of labelled cells, opening the possibility of directly detecting early changes driving cancers at the cellular level before vasculature has been fully formed. To further explore the capabilities of intracellular CAs in T1-weighted MRI of breast cancer, this work aimed at (1) demonstrating the potential of MnCl2-enhanced MRI to detect and characterize early small breast tumors in vivo (2) investigating the potential of manganese-porphyrin-enhanced MRI for sensitive detection of multiple clinical subtypes of breast cancer cells (3) utilizing quantitative MRI to demonstrate the role the balance between hydrophilicity and hydrophobicity plays in developing CAs for effective T1-weighted MRI of cancer. This work has shown that MnCl2, unlike Gd-DTPA, provided enhancement of the entire tumor mass, depicting both tumor borders and interior morphology. At the early stage of tumor growth, MnCl2 also enabled cancer subtype-dependent differential enhancement and characterization. Moreover, this work demonstrated the superior T1 enhancement capabilities of manganese porphyrins over Gd-DTPA of multiple clinical subtypes of breast cancer cells at 3.0T. Also, using quantitative MRI, the more hydrophobic manganese porphyrin, MnTPPS3NH2, is shown to be a more sensitive T1 CA than MnTPPS4 for cellular imaging of breast cancers. Such sensitive cellular detection can potentially lead to lowering the dose needed to achieve positive enhancement and merits further future in vivo investigation

Speaker
Biography:

Carlos Zepeda-Velázquez earned his BSc degree in Pharmaceutical Chemistry from La Salle University and his M.Sc. in Organic Chemistry from National Autonomous University of Mexico in 2003 and 2006 respectively. Subsequently, he worked as a process chemist at Signa, SA de CV (Apotex Pharmachem INC). For his doctoral studies he moved to Canada in 2009 and joined the group of Dr McNulty at McMaster University where he completed the total synthesis of the anticancer natural product (+)-trans-Dihydrolycoricidine. He then moved to the Ontario Institute for Cancer Research under Dr Rima Al-awar, working on novel anti-tumor agents and in 2016 he was promoted to Research Scientist. His research focuses on chemical biology of chromatin regulation and drug discovery.
 

Abstract:

At a fundamental level, gene expression is regulated by epigenetic histone modifications. Histone methyltransferases catalyze the transfer of the methyl group from S adenosylmethionine to specific lysine residues on histones. Mixed lineage leukemia 1 (MLL1) is a methyltransferase that methylates lysine 4 on histone H3 (H3K4me3) and is an important regulator of the haemopoietic system. Dysregulation of MLL1 is often associated with acute myeloid and lymphoid leukemias, making it an attractive therapeutic target. WD40 repeat protein 5 (WDR5) is a component of the multiprotein MLL1 complex that is essential for its methyltransferase activity, and disruption of the WDR5/MLL1 interaction may therefore present a viable therapeutic option for the treatment of MLL-dependent leukemias. Employing structure-based design principles and cheminformatic tools, compounds that bind to WDR5 with low nanomolar affinities were synthesized. Of the various small molecules assessed, OICR-9429 demonstrated the most potent activity with KD values of 51 nM (Biacore), 64 nM (FP) and 52 nM (ITC). OICR9429 also disrupts the interaction of WDR5 with MLL1 and RbBP5 in cells with IC50 values below 1 µM

Speaker
Biography:

Dr Romina Geraldine D’Souza, she had completed my MD Radiology from Father Muller Medical college Mangalore, India, Diplomate of the National Board in Radiology and currently doing a fellowship in Crossectional radiology in Christian Medical College, Vellore India and FRCR 2

Abstract:

Oral cavity malignancies are very highly prevalent in the Indian Subcontinent and in recent times T1 and T2 disease have become the common presentation. Upfront surgery with neck node clearance is the management of choice, however, we aim to prevent the morbidity of nodal clearance if we can prove the absence of nodal disease in the neck preoperatively. We studied 30 patients with oral malignancies who underwent surgery as primary treatment. A total of 127 lymph nodes were identified on MRI and correlated with Histopathology for the presence of metastasis. Our analysis of these nodes showed that using RECIST criteria of short axis >10 mm, has a sensitivity and specificity was 35% and 89% respectively. Thus we studied other imaging parameters that when used in combination would have a better predictive value. STIR proved to be very highly sensitive in detecting the presence of a lymph node while Extracapsular invasion, Rim enhancement, and T2 heterogeneity are highly specific for metastatic involvement. Thus a combination of STIR and any one of the specific findings provides a high Sensitivity and Negative predictive value with a reasonable Specificity which could preclude a neck dissection in c N0 patients. Diffusion studies revealed lower mean ADC in malignant nodes, however, it was not statistically significant to identify metastatic disease in subcentimeter nodes in the neck
 

Mohammed Naeem

King Abdullah Specialized Children’s Hospital, Saudi Arabia

Title: Approach to wide aspects of end of life care in children
Speaker
Biography:

Mohammed Naeem MD, FAAP, FCCP has vast interests and experience in care and development of children and adolescents. His passion gears towards constructing and implementing scientific models to improve systems targeting primary, secondary and tertiary care. His ideology takes a positive direction through his in-depth analyses and vision and further to explore multiple ways that would help understand the complex pathological phenomenon and planning to design and implement strategies to overcome these. His particular interest and expertise involves population of children and adolescents requiring intensive care. He had been utilizing his vast experience of research, clinical care, patient safety and strategic planning to ambitiously achieve his goals. Through multiple levels of participation in care and strategic planning relevant to diverse patient population, he had been very successful to make his contributions and judgments being heard and taken in considerations 

Abstract:

Goal: The aim of this work shop is to prepare pediatric health care workers (HCW) to effectively conceptualize & define concepts of end of life care, identify the child’s clinical status, utilize effective methods of communications and interactions maintain a multidisciplinary approach, ascertain the child and family’s medical and psycho-social needs, execute a formulated plan and take post death steps as an ideal HCW Background: Over the last several years, advancements in medical care of complicated medical conditions like cancers and multi-organ failure syndromes as well as general public awareness of the basic disease processes has placed emphasis on medical community to be more efficient and be prepared to make correct transition from cure to end of life care when appropriate time comes. Overall, there is a gap among HCW’s comprehension, assimilation and swift formulation of line of action regarding realizing the needs of the patients who are approaching end stages of their diseases and as well as of their families. Summary of Learning Objectives: This novel envisioned workshop shall gear the participants to learn and practice the following: 1. Use objective methods to formulate a check list regarding patient’s current medical status 2. Use effective methods of communication to approach patients and their families 3. Identify the medical needs of the patients regarding end of life care 4. Identify medico-legal role of HCW in assistance of post death proceedings
 

Speaker
Biography:

Abstract:

Our research indicated that optimal dose of Vitamin D3 has following 10 unique beneficial effects: 1) significant Anti-cancer effects without side effects, 2) marked decrease in DNA mutation which is proportional to the decrease in 8-OH-dG, 3) marked urinary excretion of Viruses, Bacteria, Fungi, single-cell parasites, & Toxic substances, including Asbestos & metals such as Hg, Pb, & Al, 4) marked increase in Acetylcholine in the brain & the rest of the body, 5) marked increase in DHEA, 6) marked decrease in β-Amyloid (1-42) in brain, 7) marked decrease in Cardiac Troponin I, 8) marked increase in Thymosin α1 (which has natural, powerful, anti-cancer effects & anti-inflammatory effects and enhanced immune system, 9) Thymosin β4 (which has significant improvement in circulatory system), & 10) anti-allergic effects. Although it is well-known that in uterus cancer, ovarian cancer, & breast cancer, Human Papilloma Virus-Type 16 (HPV-16) is involved. We found almost every cancer tissue has HPV-16 infection. In addition, some of the rapidly developed cancer patients, often find mixed co-existing infections of HPV-16, single-cell parasite Toxoplasma Gondii. Our recent research indicated that almost every part of single-cell parasite Toxoplasma Gondii’s cell has a viral infection of Human Herpes Virus-Type 8 (HHV-8). Therefore, most cancer patients have viral infection of HPV-16 with HHV-8. These infections are for some reason about almost same ratio of weight. When the degree of these infections are very high, in presence of other co-existing cancer-promoting factors, cancer can develop very rapidly. Among these important contributing co-existing cancer-promoting factors are repeated exposure of electromagnetic field (EMF), foods & drinks with undesirable contributing factors, harmful underwear, toxic substances or decorations directly touching the skin. Based on the analysis of these problems, we also found most of the eggs from chickens are also infected with HPV-16 & Toxoplasma Gondii with HHV-8. However, these infections only exist at egg yolk and egg white does not have these viral infections. In order to solve these problems, most safe & practical way we develop new method of treating various cancers by the combination of the following 4 methods: 1) Individualized optimal dose of Vitamin D3 using its 10 unique, beneficial effects, 2) Selective drug uptake enhancement method, 3) Manual stimulation of Thymus gland or its representation areas on the back of the hand, & 4) Identification & removal of co-existing major cancer-promoting factors. For example, in the early stage of cancer, when Integrin α5β1 as well as Oncogene CfosAb2 are always increased. In the early stage of cancer when Integrin α5β1 becomes increased about close to 200ng, standard laboratory tests can often confirm presence of cancer using the MRI or other imaging techniques. We use 8-OH-dG to evaluate the aggressiveness of the cancer. Usually, in early stage of cancer, it is 2.5ng. 8-OH-dG is proportional to DNA mutation. DNA mutation is necessary in order for cancer cells to grow. When patient’s condition is advanced & terminal stage, Integrin α5β1 is usually over 1500ng, with metastasis & 8-OHdG becomes 60~80ng or higher. In these patients, when we give individually determined optimal dose of Vitamin D3, for example, Integrin α5β1 of over 1500ng becomes 0.002~0.004ng within 30 minutes after taking individualized optimal dose of Vitamin D3. 8-OH-dG of 60~80ng or higher often reduces to 0.2ng which is within normal range. This significant reduction cannot be compared with many existing standard cancer treatments. Average effective duration of optimal dose of Vitamin D3 is about 8 hours. Therefore, the beneficial effects last average of about 8 hours and you have to take optimal dose every 8 hours. If room temperature is very high, effective time duration reduces to 6~7 hours. If more than 200~300mg of Vitamin C is taken, effect of Vitamin D3 will be completely cancelled. Any food or drink containing large amount of Vitamin C or a fruit with Vitamin C such as lemon juice or orange juice should be avoided. One optimal dose of Vitamin D3 also improves Acetylcholine in the brain & rest of the body. As a result, brain function including memory, concentration, & motor function improves very significantly, particularly for those who have low Acetylcholine levels of 1ng or less. Very strong infection of HPV-16 & HHV-8 markedly reduces from body from over 7000ng to safe range of 500~300ng and large amount of viruses are excreted in urine. Urinary excretion of each virus often increases to 2000~3000ng. Cardiac Troponin I significantly reduces toward normal value due to improvement of cardiovascular circulatory system. In order for optimal dose of Vitamin D3 to reach pathological organ selectively, the author discovered selective drug uptake enhancement method more than 15 years ago by manually stimulating accurate organ representation areas of the hand. In order to make immune system very active, manual stimulation of Thymus gland or its representation areas, particularly at the back of the hand which author discovered in 2017. This makes it the safest treatment without side effects but there are always multiple, major co-existing, cancer-promoting factors. Therefore, our treatment includes identification of major co-existing cancer-contributing factors & removing them. By taking optimal dose of Vitamin D3, both Thymosin α1 & Thymosin β4 increase significantly but additional stimulation of Thymus gland representation area, both Thymosins can reach over 100~150ng from normal value of 5~10ng which enhances both improvements in circulation as well as significantly enhanced immune system